Paul Maier has been confirmed as chief financial officer and Ronald Lindsay as senior vice president of research and development of Sequenom. Both had held their positions on an interim basis since last fall.
Prior to becoming Sequenom's interim CFO, Maier was an independent consultant, and before that, senior vice president and CFO of Ligand Pharmaceuticals from 1992 until 2007. He holds an MBA from Harvard University.
Lindsay, a Sequenom director since 2003, previously operated Milestone Consulting, a biopharmaceutical consulting firm. Before that, he was vice president of research and development and chief science officer of DiaDexus from 2000 until 2004. He holds a PhD in biochemistry from the University of Calgary.
George Church and Ron Davis have joined Pathogenica's science advisory board. Pathogenica is a Cambridge, Mass.-based company and is focused on developing flexible, high-throughput, and low-cost sequencing-based assays for the medical diagnostics and biosurveillance markets.
Church is a professor of genetics at Harvard Medical School, and has founded or advised 24 biotechnology companies including Knome, Complete Genomics, and 23andMe.
Davis is the director of the Stanford Genome Technology Center; a cofounder of ParAllele, which was acquired by Affymetrix; and an advisor to Ion Torrent.